Osaic Holdings’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,785
| Closed | -$1.35K | – | 7864 |
|
|
2025
Q3 | $1.35K | Hold |
1,785
| – | – | ﹤0.01% | 7258 |
|
|
2025
Q2 | $2K | Buy |
1,785
+66
| +4% | +$74 | ﹤0.01% | 6936 |
|
|
2025
Q1 | $2.16K | Sell |
1,719
-196
| -10% | -$347 | ﹤0.01% | 6561 |
|
|
2024
Q4 | $4.34K | Buy |
1,915
+1,214
| +173% | +$2.24K | ﹤0.01% | 6269 |
|
|
2024
Q3 | $2.42K | Hold |
701
| – | – | ﹤0.01% | 6538 |
|
|
2024
Q2 | $3.58K | Hold |
701
| – | – | ﹤0.01% | 6335 |
|
|
2024
Q1 | $5.89K | Sell |
701
-15
| -2% | -$82 | ﹤0.01% | 6008 |
|
|
2023
Q4 | $2.93K | Sell |
716
-283
| -28% | -$848 | ﹤0.01% | 6383 |
|
|
2023
Q3 | $3K | Buy |
999
+283
| +40% | +$6.43K | ﹤0.01% | 6469 |
|
|
2023
Q2 | $22.1K | Sell |
716
-13
| -2% | -$539 | ﹤0.01% | 5497 |
|
|
2023
Q1 | $36K | Sell |
729
-7
| -1% | -$203 | ﹤0.01% | 5185 |
|
|
2022
Q4 | $16K | Buy |
736
+13
| +2% | +$486 | ﹤0.01% | 5702 |
|
|
2022
Q3 | $48K | Hold |
723
| – | – | ﹤0.01% | 4930 |
|
|
2022
Q2 | $31K | Hold |
723
| – | – | ﹤0.01% | 5308 |
|
|
2022
Q1 | $1.33M | Buy |
723
+48
| +7% | +$2.36K | ﹤0.01% | 2308 |
|
|
2021
Q4 | $40K | Sell |
675
-53
| -7% | -$2.61K | ﹤0.01% | 5298 |
|
|
2021
Q3 | $37K | Hold |
728
| – | – | ﹤0.01% | 5327 |
|
|
2021
Q2 | $42K | Sell |
728
-871
| -54% | -$46.5K | ﹤0.01% | 5168 |
|
|
2021
Q1 | $92K | Buy |
1,599
+148
| +10% | +$11.2K | ﹤0.01% | 4405 |
|
|
2020
Q4 | $99K | Sell |
1,451
-2,289
| -61% | -$312K | ﹤0.01% | 4047 |
|
|
2020
Q3 | $948K | Buy |
3,740
+3,220
| +619% | +$659K | ﹤0.01% | 1880 |
|
|
2020
Q2 | $87K | Sell |
520
-47
| -8% | -$5.07K | ﹤0.01% | 3781 |
|
|
2020
Q1 | $40K | Buy |
+567
| New | +$44.3K | ﹤0.01% | 4142 |
|
Osaic Holdings's BCLI Position: Q4 2025 in Review
Osaic Holdings sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2025, closing a stake of 1,785 shares — an estimated $1.35K sold.
Osaic Holdings first reported a position in BCLI in Q1 2020 and held it in 23 quarters. The position peaked at $1.33M in Q1 2022. 0 funds tracked by Wall St. Rank hold BCLI as of Q4 2025.
- Osaic Holdings reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2025 after selling out during the quarter.
- Osaic Holdings sold 1,785 BRAINSTORM CELL THERAPUTC shares in Q4 2025, an estimated $1.35K.
- Osaic Holdings first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 23 quarters.
- Osaic Holdings's BRAINSTORM CELL THERAPUTC position peaked at $1.33M in Q1 2022.
- 0 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2025.
Based on Osaic Holdings's 13F filing for Q4 2025, filed 17 Feb 2026.